City
Epaper

S. Korea to ban remote prescription of weight loss medication

By IANS | Updated: November 29, 2024 16:50 IST

Seoul, Nov 29 South Korea's health ministry on Friday said it will ban remote prescribing of weight loss ...

Open in App

Seoul, Nov 29 South Korea's health ministry on Friday said it will ban remote prescribing of weight loss medications, including Wegovy, released in the country in October, to prevent potential abuse.

According to the Ministry of Health and Welfare, the decision to ban remote prescribing of weight loss medications will take effect Monday, with a two-week grace period, Yonhap news agency reported.

The move comes amid growing concerns over the abuse and illegal sales of such medications, particularly due to the growing popularity of Wegovy, which was developed by Denmark-based Novo Nordisk.

The government also plans to establish guidelines for telemedicine consultations regarding such medications within the first half of 2025, the health ministry added.

South Korea has been temporarily allowing telemedicine consultations amid the ongoing walkout by trainee doctors at general hospitals, which began in February.

Wegovy was launched in South Korea on November 15. It is a weight management medication that can treat obesity and has gained international attention as a “miracle weight loss drug”.

The Health Ministry stressed that medical institutions should “avoid promoting the drug in ways that might lead patients to believe it can be easily prescribed for general weight loss purposes” and “take special precautions to prevent misuse when prescribing through telemedicine.”

As per the current regulations, Wegovy must only be prescribed to patients with a body mass index (BMI) of 30 or higher. Adults with a BMI between 27 and 30 who have conditions such as hypertension or dyslipidemia can also be prescribed the drug.

The Health Ministry has also requested medical institutions to comply with the Food and Drug Safety Administration’s approval conditions. Before prescribing the medication, patients must be informed about potential side effects, which include gallbladder disease and pancreatitis, it said.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

EntertainmentShivangi Verma clears the air on her link-up rumors with Govind Namdev

BusinessSaturo Technologies Launches Saturo Academy to Empower IT Professionals with Future-Ready Skills

NationalFIR registered against PG student for Instagram post opposing 'Operation Sindoor'

InternationalNuclear option "not on the cards right now", says Pak Defence Minister amid rising tensions between India, Pakistan

BusinessStay Alert, Stay Safe: Chandigarh's Cyber Wellness Clinic Opens to Fight Cybercrime

Health Realted Stories

HealthHeart rhythm disorder traces to bacterium lurking in gums: Study

HealthStudy shows weight-loss drugs can cut alcohol intake by almost two-thirds

HealthThis cholesterol pill may fight high risk of heart attack, stroke: Study

HealthIndia continues to witness significant improvement in key maternal, child health indicators: Report

HealthGujarat govt expands 542 general ambulances into 108 emergency service network